Skip to main content

Market Overview

Decibel Therapeutics' Hearing Loss Gene Therapy Shows Potential In Preclinical Studies

  • Decibel Therapeutics Inc (NASDAQ: DBTXpresented preclinical data of its gene therapy candidate, DB-OTO, for hearing loss due to mutation of the otoferlin gene.
  • Decibel presented the data at the Annual MidWinter Meeting of the Association for Research in Otolaryngology.
  • DB-OTO is delivered via surgical procedure during a standard cochlear implantation procedure.
  • Studies highlighted successful distribution and expression across the cochlear length, as well as well tolerated.
  • Data suggested hair cell-selective expression of otoferlin may enable greater efficacy and durability and minimize potential toxicity.
  • The therapy also demonstrated that DB-OTO restored normal hearing sensitivity in animal models of otoferlin deficiency.
  • Decibel is developing DB-OTO in collaboration with Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and expects to submit an Investigational New Drug/Clinical Trial Application for human trials in 2022.
  • Price Action: DBTX increased 4.94% at $18.90, and REGN is down 1.072% at $463.03 in market trading hours on the last check Wednesday.

Related Articles (REGN + DBTX)

View Comments and Join the Discussion!

Posted-In: Hearing loss Phase 1 TrialBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at